iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
复制标题
DOI：
10.1182/blood-2017-09-806398
复制
发表时间：
2018-06-21
期刊：
影响因子：
20.3
通讯作者：
Kipps, Thomas J.
中科院分区：
文献类型：
--
作者：
Hallek, Michael;Cheson, Bruce D.;Kipps, Thomas J.
2008年出版的国际慢性淋巴细胞白血病研讨会（iwCLL）共识指南的上一版已被照顾CLL患者的医生和研究人员广泛接受。最近的进展包括发现疾病的基因组景观，开发具有预后相关性的基因检测，以及检测微小残留病（MRD），再加上具有令人印象深刻疗效的新型靶向药物的可用性增加，促使国际小组提供最新的证据和专家意见为基础的建议。这些建议包括iwCLL反应标准的修订版本，关于使用MRD状态进行临床评价的更新，以及关于CLL管理期间病毒性疾病的评估和预防的建议。
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.